Search Results - "LaMoreaux, Brian"

Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk by Feaver, Ryan E, Bowers, M. Scott, Cole, Banumathi K, Hoang, Steve, Lawson, Mark J, Taylor, Justin, LaMoreaux, Brian D, Zhao, Lin, Henke, Brad R, Johns, Brian A, Nyborg, Andrew C, Wamhoff, Brian R, Figler, Robert A

“…Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For…”
Get full text

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation by Holladay, Emily E, Mudano, Amy S, Xie, Fenglong, Zhang, Jingyi, Mikuls, Ted R, LaMoreaux, Brian, Padnick-Silver, Lissa, Curtis, Jeffrey R

“…Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate…”
Get full text

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial by Botson, John K, Obermeyer, Katie, LaMoreaux, Brian, Zhao, Lin, Weinblatt, Michael E, Peterson, Jeff

“…Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally…”
Get full text

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study by Albert, John A., Hosey, Tony, LaMoreaux, Brian

“…Introduction Gout is a painful inflammatory condition caused by chronically elevated serum uric acid levels (sUA). When standard urate-lowering therapies…”
Get full text

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study by Botson, John K, Tesser, John R P, Bennett, Ralph, Kenney, Howard M, Peloso, Paul M, Obermeyer, Katie, Song, Yang, LaMoreaux, Brian, Zhao, Lin, Xin, Yan, Chamberlain, Jason, Ramanathan, Srini, Weinblatt, Michael E, Peterson, Jeff

“…Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR…”
Get full text

Comparison Between Early-Onset and Common Gout: A Systematic Literature Review by Amatucci, Anthony J., Padnick-Silver, Lissa, LaMoreaux, Brian, Bulbin, David H.

“…Introduction Gout is an inflammatory, metabolic disease associated with a high comorbidity burden including cardiovascular disease, hypertension, type 2…”
Get full text

Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study by Card-Gowers, Joshua, Retat, Lise, Kumar, Ada, Marder, Brad A., Padnick-Silver, Lissa, LaMoreaux, Brian, Webber, Laura

“…Introduction Gout, a common comorbidity of chronic kidney disease (CKD), is associated with high morbidity and healthcare utilization. However, a large…”
Get full text

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices by Majjhoo, Amar, Kumar, Ada, Zdanis, Michael, LaMoreaux, Brian

“…Background Pegloticase is a recombinant porcine-like uricase enzyme that is FDA-approved for the treatment of chronic refractory gout in adults. Some patients…”
Get full text

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings by Botson, John K., Saag, Kenneth, Peterson, Jeff, Obermeyer, Katie, Xin, Yan, LaMoreaux, Brian, Padnick‐Silver, Lissa, Verma, Supra, Grewal, Suneet, Majjhoo, Amar, Tesser, John R. P., Weinblatt, Michael E.

“…Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX) versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled,…”
Get full text

Social Listening in Gout: Impact of Proactive vs. Reactive Management on Self-Reported Emotional States by Flurie, Maurice, Converse, Monica, Wassman, E. Robert, LaMoreaux, Brian, Edwards, N. Lawrence, Flowers, Colton, Hernandez, Daniel, Hernandez, Helen W., Ho, Gary, Parker, Christopher, DeFelice, Christopher, Picone, Maria

“…Introduction This study aimed to characterize patient-reported outcomes from social media conversations in the gout community. The impact of management…”
Get full text

Economic and Health Care Resource Use Burden of Systemic Sclerosis by Khanna, Dinesh, Furst, Daniel E., Li, Justin W., Meng, Qian, Yuan, Yuan, Lesperance, Tamara, Peoples, Kenyatta, Ali, Farah, LaMoreaux, Brian, Taylor, Stephanie D.

“…Objective To describe the health care resource use (HCRU) and costs of patients with systemic sclerosis (SSc) prior to and after diagnosis. Methods This…”
Get full text

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase by Keenan, Robert T., Baraf, Herbert S. B., LaMoreaux, Brian

“…Introduction The aim of this work is to evaluate the impact of the timing of pre-infusion serum uric acid (sUA) test results for use in applying stopping rules…”
Get full text

Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist by LaMoreaux, Brian, MD, Barbar-Smiley, Fatima, MD, Ardoin, Stacy, MD, Madhoun, Hareth, DO

“…Abstract Introduction Romiplostim is a thrombopeitin-receptor agonist approved for raising platelet counts in patients with immune thrombocytopenia (ITP)…”
Get full text

New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation by Li, Justin W., Yin, David, Wang, Zheng, Brigham, Mark D., LaMoreaux, Brian D., Kent, Jeffrey D., Francis-Sedlak, Megan, Johnson, Richard J., Hadker, Nandini, Francis, Kevin M., Sanchez, Herman A., Miyasato, Gavin

“…The causal relationship between gout and renal transplant outcomes is difficult to assess due to multiple interacting covariates. This study sought to estimate…”
Get full text

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis by Lovell, Daniel J, Dare, Jason A, Francis-Sedlak, Megan, Ball, Julie, LaMoreaux, Brian D, Von Scheven, Emily, Reinhardt, Adam, Jerath, Rita, Alpan, Oral, Gupta, Ramesh, Goldsmith, Donald, Zeft, Andrew, Naddaf, Henry, Gottlieb, Beth, Jung, Lawrence, Holt, Robert J

“…Juvenile idiopathic arthritis (JIA) is an inflammatory arthritis of unknown etiology, which lasts for greater than 6 weeks with onset before 16 years of age…”
Get full text

Enhancing the Response Rate to Recombinant Uricases in Patients with Gout by Schlesinger, Naomi, Padnick-Silver, Lissa, LaMoreaux, Brian

“…Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower…”
Get full text

Blood Pressure Changes with Intensive Urate Lowering in Uncontrolled Gout Patients with and Without CKD: SA-PO505 by Marder, Brad A., Johnson, Richard J., Choi, Hyon, Obermeyer, Katie L., LaMoreaux, Brian, Lipsky, Peter E.

Get full text

Projected Benefits of Gout Control on the Health and Economic Burden of CKD Patients with Uncontrolled Gout: FR-PO921 by Marder, Brad A., Card-Gowers, Joshua, Retat, Lise, Piotrowski, Marek, Webber, Laura, LaMoreaux, Brian, Kumar, Ada

Get full text

Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series by Albert, John, Broadwell, Aaron, Padnick-Silver, Lissa, Marder, Brad, LaMoreaux, Brian

“…Chronic kidney disease (CKD) and gout commonly co-occur. Pegloticase lowers serum urate (SU) in uncontrolled gout patients but antidrug antibodies limit…”
Get full text

Treatment Response in Patients with Uncontrolled Gout Co-Treated with Pegloticase and Leflunomide: PUB035 by Masri, Karim R., Winterling, Kevin W., LaMoreaux, Brian

Get full text